Identification of characteristics associated with long-term survival in patients with metastatic urothelial carcinoma (mUC) who received durvalumab (D) with or without tremelimumab... von Alt, Marie, Stecca, Carlos, Kabadi, Shaum, Kazeem, Benga, Sridhar, Srikala S.

Volltext

DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) i... von Mateos, Maria Victoria, Robak, Pawel, Hus, Marek, Fu, ChengCheng, Zherebtsova, Vera, Ward, Christopher, Joy Ho, P., Carolina de Almeida, Ana, Hajek, Roman, Kim, Kihyun, Dimopoulos, Meletios, Cerchione, Claudio, Pirooz, Nick, McKeown, Astrid, Kazeem, Benga, Baig, Hena, Eccersley, Lydia, Roy-Ghanta, Sumita, Opalinska, Joanna, Hungria, Vania

Volltext

P-396 Characterization and Management of Ocular Events in Patients (Pts) Treated With Belantamab Mafodotin (Belamaf) Plus Bortezomib and Dexamethasone (BVd) in the DREAMM-7 Study von Hungria, Vania T.M., Robak, Pawel, Hus, Marek, Fu, Chengcheng, Zherebtsova, Vera, Ward, Christopher, Ho, P. Joy, Hájek, Roman, Kim, Kihyun, de Lacerda, Marcelo Pitombeira, Aparecida-Martinez, Gracia, Dimopoulos, Meletios, Cerchione, Claudio, Pirooz, Nick, McKeown, Astrid, Rogers, Rachel, Kazeem, Benga, Wang, Zhaohui, Baig, Hena, Eccersley, Lydia, Roy-Ghanta, Sumita, Opalinska, Joanna, Manteca, María-Victoria Mateos

Volltext